MarketCapExport financials
Progenity, Inc. (PROG)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
TelegramProgenity, Inc. Financial Ratios 2020-2011 | PROG
Annual Financial Ratios Progenity, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.8 | - | - | - | - | - | - | - | - | - | |
P/S |
4.6 | - | - | - | - | - | - | - | - | - |
EV/EBITDA |
-2.2 | - | - | - | - | - | - | - | - | - |
PEG |
0.06 | - | - | - | - | - | - | - | - | - |
P/B |
-3.2 | - | - | - | - | - | - | - | - | - |
P/CF |
-2.0 | - | - | - | - | - | - | - | - | - |
ROE % |
179.94 | - | - | - | - | - | - | - | - | - |
ROA % |
-124.66 | - | - | - | - | - | - | - | - | - |
ROCE % |
-238.70 | - | - | - | - | - | - | - | - | - |
DSO |
62.3 | - | - | - | - | - | - | - | - | - |
DIO |
47.7 | - | - | - | - | - | - | - | - | - |
DPO |
68.0 | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company Progenity, Inc., allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Biotechnology industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Galectin Therapeutics
GALT
|
$ 2.98 | -14.12 % | $ 190 M |  USA |
 |
Corcept Therapeutics Incorporated
CORT
|
$ 71.75 | -9.43 % | $ 7.45 B | USA |
 |
Genprex
GNPX
|
$ 2.09 | -2.34 % | $ 1.95 M | USA |
 |
Strongbridge Biopharma plc
SBBP
|
- | 1.52 % | $ 136 M | USA |
 |
Innate Pharma S.A.
IPHA
|
$ 1.4 | -1.76 % | $ 125 M |  France |
 |
Seneca Biopharma, Inc.
SNCA
|
- | -1.19 % | $ 28.7 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
$ 56.14 | -1.74 % | $ 10.8 B | USA |
 |
Matinas BioPharma Holdings
MTNB
|
$ 1.11 | -7.0 % | $ 6.08 M | USA |
 |
Enanta Pharmaceuticals
ENTA
|
$ 10.06 | -5.54 % | $ 215 K | USA |
 |
Milestone Pharmaceuticals
MIST
|
$ 0.69 | -10.54 % | $ 73.3 M |  Canada |
 |
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
$ 88.15 | -8.29 % | $ 6.54 B | USA |
 |
Lipocine
LPCN
|
$ 1.52 | 5.56 % | $ 8.28 M | USA |
 |
Seres Therapeutics
MCRB
|
$ 2.09 | -2.63 % | $ 18.5 M | USA |
 |
Madrigal Pharmaceuticals
MDGL
|
$ 400.26 | -0.04 % | $ 8.98 B | USA |
 |
CEL-SCI Corporation
CVM
|
$ 1.35 | -2.88 % | $ 10.8 M | USA |
 |
Inventiva S.A.
IVA
|
$ 3.65 | -5.68 % | $ 218 M | France |
 |
MeiraGTx Holdings plc
MGTX
|
$ 8.51 | -9.71 % | $ 684 M | USA |
 |
Eton Pharmaceuticals
ETON
|
$ 47.29 | -6.76 % | $ 1.27 B | USA |
 |
IDEAYA Biosciences
IDYA
|
$ 30.63 | -5.35 % | $ 2.71 B | USA |
 |
Lantern Pharma
LTRN
|
$ 0.55 | -5.33 % | $ 5.99 M | USA |
 |
Foghorn Therapeutics
FHTX
|
$ 1.9 | -9.52 % | $ 120 M | USA |
 |
Minerva Neurosciences
NERV
|
$ 2.3 | -10.7 % | $ 19.5 M | USA |
 |
Kamada Ltd.
KMDA
|
$ 6.89 | -7.14 % | $ 397 M |  Israel |
 |
Neurocrine Biosciences
NBIX
|
$ 159.9 | -3.7 % | $ 15.9 B | USA |
 |
Nanobiotix S.A.
NBTX
|
$ 29.92 | 0.74 % | $ 1.43 T | France |
 |
Mereo BioPharma Group plc
MREO
|
$ 0.28 | -7.49 % | $ 223 M |  Britain |
 |
Maravai LifeSciences Holdings
MRVI
|
$ 6.94 | -10.1 % | $ 1 B | USA |
 |
Lexicon Pharmaceuticals
LXRX
|
$ 1.61 | 8.78 % | $ 585 M | USA |
 |
Moleculin Biotech
MBRX
|
$ 8.72 | 3.07 % | $ 10.3 M | USA |
 |
Nurix Therapeutics
NRIX
|
$ 14.83 | -7.02 % | $ 1.29 B | USA |
 |
Nkarta
NKTX
|
$ 1.59 | -8.38 % | $ 118 M | USA |
 |
MacroGenics
MGNX
|
$ 2.24 | -3.25 % | $ 141 M | USA |
 |
ImmuCell Corporation
ICCC
|
$ 9.88 | -4.77 % | $ 89.2 M | USA |
|
Nuvation Bio
NUVB
|
$ 4.19 | -11.42 % | $ 1.43 B | USA |
 |
Novo Nordisk A/S
NVO
|
$ 40.27 | -4.52 % | $ 179 B |  Danmark |
 |
Marker Therapeutics
MRKR
|
$ 0.9 | -11.24 % | $ 13.8 M | USA |
 |
NextCure
NXTC
|
$ 5.16 | -12.39 % | $ 14.7 M | USA |
 |
Olema Pharmaceuticals
OLMA
|
$ 6.89 | -8.62 % | $ 599 M | USA |
 |
Kymera Therapeutics
KYMR
|
$ 124.88 | -8.34 % | $ 10.6 B | USA |
 |
Oragenics
OGEN
|
$ 0.34 | -9.47 % | $ 733 K | USA |
 |
Ovid Therapeutics
OVID
|
$ 2.59 | -5.66 % | $ 337 M | USA |
 |
Passage Bio
PASG
|
$ 3.44 | -2.14 % | $ 11 M | USA |
 |
Vaxcyte
PCVX
|
$ 62.47 | -4.89 % | $ 8.5 B | USA |
 |
Precigen
PGEN
|
$ 4.2 | -16.94 % | $ 1.31 B | USA |
 |
Phio Pharmaceuticals Corp.
PHIO
|
$ 0.81 | -7.25 % | $ 4.85 M | USA |
 |
Praxis Precision Medicines
PRAX
|
$ 262.42 | -7.85 % | $ 5.91 B | USA |
 |
Prelude Therapeutics Incorporated
PRLD
|
$ 3.55 | -12.99 % | $ 273 M | USA |
 |
ProQR Therapeutics N.V.
PRQR
|
$ 1.34 | -5.32 % | $ 141 M |  Niderland |
 |
Ocular Therapeutix
OCUL
|
$ 6.48 | -9.31 % | $ 1.21 B | USA |